Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Niagen Bioscience (NAGE) over the last 16 years, with Q3 2025 value amounting to $1.8 million.

  • Niagen Bioscience's Share-based Compensation rose 13891.16% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 2867.29%. This contributed to the annual value of $3.7 million for FY2024, which is 2304.78% down from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Share-based Compensation is $1.8 million, which was up 13891.16% from $1.5 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Share-based Compensation high stood at $1.9 million for Q1 2022, and its period low was $735000.0 during Q3 2024.
  • In the last 5 years, Niagen Bioscience's Share-based Compensation had a median value of $1.3 million in 2021 and averaged $1.3 million.
  • As far as peak fluctuations go, Niagen Bioscience's Share-based Compensation plummeted by 3419.87% in 2024, and later surged by 13891.16% in 2025.
  • Quarter analysis of 5 years shows Niagen Bioscience's Share-based Compensation stood at $1.5 million in 2021, then decreased by 9.98% to $1.3 million in 2022, then dropped by 21.79% to $1.0 million in 2023, then fell by 27.48% to $752000.0 in 2024, then skyrocketed by 133.51% to $1.8 million in 2025.
  • Its Share-based Compensation stands at $1.8 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.1 million for Q1 2025.